1 **Remedial dosing recommendation for delayed or missed rivaroxaban doses for**
2 **patients with non-valvular atrial fibrillation based on Monte Carlo simulation**

3 Xiao-qin Liu^{1,2}, Yi-wei Yin¹, Chen-yu Wang¹, Zi-ran Li^{1,2}, Xiao Zhu³, Zheng Jiao^{1*}

4 ¹ Department of Pharmacy, Shanghai Chest Hospital, Shanghai Jiao Tong University,
5 Shanghai, China

6 ² Department of pharmacy, Huashan Hospital, Fudan University, Shanghai, China

7 ³ School of Pharmacy, University of Otago, Dunedin, New Zealand

8

9 Xiao-qin Liu and Yi-wei Yin contributed equally to this work.

10

11 ***Corresponding author:**

12 Zheng Jiao, Professor

13 Department of Pharmacy, Shanghai Chest Hospital, Shanghai Jiao Tong University

14 241 Huaihai West Road, Shanghai, China, 200030

15 Tel.: +86 (21) 2220 0000

16 E-mail: jiaozhen@online.sh.cn

17 ORCID: 0000-0001-7999-7162

18 **Abstract**

19 **Background** Rivaroxaban is a non-vitamin K oral anticoagulant used widely for
20 stroke prevention in patients with non-valvular atrial fibrillation (NVAf). During
21 long-term anticoagulant therapy, delayed or missed doses are common. However, a
22 lack of practical instructions on remedial methods has created a barrier for patients to
23 maximise the benefit of their medications. This study aimed to explore appropriate
24 remedial dosing regimens for rivaroxaban-treated patients with NVAf.

25 **Methods** Monte Carlo simulation based on a previously established rivaroxaban
26 population pharmacokinetic/pharmacodynamic model for patients with NVAf was
27 employed to design remedial dosing regimens. Both the European Heart Rhythm
28 Association (EHRA) recommendations and the model were used to establish remedial
29 dosing regimens, which were assessed considering the on-therapy range of drug
30 concentration, factor Xa activity, and prothrombin time under various scenarios of
31 non-adherence.

32 **Results** Recommendations of EHRA guide may not be optimal. Our findings
33 suggested that a missed dose is taken immediately when the delay is less than or equal
34 to 6 h; a half dose is advisable when the delay exceeds 6 h but is less than 4 h before
35 the next dose. It is recommended to skip a dose when there are less than 4 h before the
36 next dose. Age or renal function do not significantly influence the remedial dosing
37 regimen.

38 **Conclusion** A remedial dosing regimen based on model-based Monte Carlo
 39 simulation was systematically developed for rivaroxaban-treated patients with NVA
 40 with poor adherence to quickly restore drug concentrations to the on-therapy range
 41 and to reduce the risk of bleeding and thromboembolism.

42 **Key words:** anticoagulation, rivaroxaban, non-adherence, Monte Carlo simulation,
 43 population pharmacokinetics and pharmacodynamics

What is known on this topic?

- Remedial recommendations for delayed or missed rivaroxaban dose have been mentioned in package inserts and guide, but lack of solid supporting evidence.
- Monte Carlo simulation based on population analysis have been proved as an appropriate method to explore the remedial dosing strategy.

What does this paper add?

- Remedial recommendations for delayed or missed rivaroxaban in different population are established based on Monte Carlo simulation.
- The choice of optimal remedial strategy is related to delay duration.
- This paper provides a more time-specific and individualized recommendations compared with previous recommendations.

1 **1 Introduction**

2 Rivaroxaban is one of the most commonly used non-vitamin K oral anticoagulants
3 (NOACs), and was the first oral direct factor α ($F\alpha$) inhibitor approved for stroke
4 prevention in patients with non-valvular atrial fibrillation (NVAF) ¹⁻⁵. More than
5 two-thirds of rivaroxaban doses are excreted by the kidney as metabolites or
6 unchanged drugs ^{6,7}; therefore, dose adjustment based on renal function is required in
7 patients with moderate renal impairment (creatinine clearance, CrCl, 30–49 mL/min) ²
8 to achieve consistent efficacy and safety, when compared with the case in individuals
9 with normal renal function ⁸.

10 Patients with NVAF receiving anticoagulant therapy usually require long-term
11 therapy; however, adherence to NOACs, including rivaroxaban, decreases over time.

12 In a large retrospective study, adherence to rivaroxaban was 68% 3 months after
13 treatment initiation, and decreased to 50% after 12 months of treatment ⁹.

14 Additionally, a considerable proportion of NVAF patients are elderly (> 70 years) ^{10,11}.

15 Delayed or missed doses, which represent a major form of non-adherence in clinical
16 practice, is common in this population of elderly patients ^{12,13}. As a class of drugs

17 with fast on/fast off characteristics ¹⁴, non-adherence is associated with an increasing
18 risk of thromboembolic events ¹⁵. For example, a 10% decrease in dabigatran

19 adherence, another NOAC, results in a 13% increase in all-cause mortality and stroke

20 ¹⁶. Therefore, appropriate remedial dosing for patients with poor adherence is

21 necessary to minimise the occurrence of thromboembolic events. Developing an
22 appropriate remedial regimen is essential for the prevention of overdose-related
23 bleeding events and underdose-related thromboembolic events caused by
24 inappropriate remedial dosing. By providing scenario-specific instructions, patients
25 can maximise the benefit and minimise the risk associated with rivaroxaban therapy.
26 Several resources provide recommendations for patients who experience a delayed or
27 missed dose. The package inserts from the United States Food and Drug
28 Administration (US FDA) states that ‘the patient should take the missed rivaroxaban
29 dose immediately. The dose should not be doubled within the same day to make up
30 for a missed dose’². Similar recommendations are found in patient information
31 leaflets¹⁷ and consumer medicine information¹⁸. Furthermore, the 2018 European
32 Heart Rhythm Association (EHRA) practical guide on the use of non-vitamin K
33 antagonist oral anticoagulant in patients with atrial fibrillation recommends that ‘for
34 NOACs with a once-a-day dosing regimen, a delayed dose can be taken up until 12 h
35 after the scheduled intake. After this time point, the dose should be skipped, and the
36 next scheduled dose should be taken’¹⁹. However, these recommendations are not
37 supported by solid evidence from clinical studies or by extrapolation from
38 pharmacokinetic/pharmacodynamic (PK/PD) analyses. It is also uncertain whether the
39 recommendation can be applied to patients with impaired renal function.
40 Although human studies are ideal for assessing proposed remedial regimen,
41 prospective clinical research is unethical, and post-marketing adherence data are

usually inadequate to explore the effects of non-adherence and to investigate appropriate remedial doses ²⁰. Monte Carlo simulations based on established population PK/PD models provide a practical approach to overcome this problem and have been successfully applied to antiepileptic, antipsychotic, and immunosuppressive agents ²¹. Therefore, this study aimed to (i) assess the effect of delayed dose on the PK/PD of rivaroxaban and (ii) explore appropriate remedial dosing regimens by Monte Carlo simulation for patients with NVAf receiving rivaroxaban.

2 Materials and methods

2.1 Patients and dosing regimen

Adult patients (aged 55 or 75 years old) with various levels of creatinine clearance (CrCl, calculated by the Cockcroft-Gault formula ²²) were simulated, including patients with normal and moderately impaired renal function (CrCl 80 and 40 mL/min, respectively). The demographic characteristics of patients with NVAf were collected from epidemiologic reports ^{10,11,23}. As indicated on the US FDA label ² and as recommended in the 2018 EHRA guide ¹⁹, patients with CrCl ≥ 50 mL/min received rivaroxaban 20 mg every 24 h (q24h), and those with CrCl 30–49 mL/min received 15 mg q24h. It was assumed that patients take rivaroxaban with food at the same time every day. Demographic information and simulated dosing regimens for typical patients are listed in [Table 1](#).

2.2 Remedial dosing regimen assessment

62 For patients with NVAf taking rivaroxaban 20 or 15 mg daily, various scenarios were
63 investigated in which doses were delayed from 1 to 24 h after the scheduled time
64 ([Figure 1](#)).

65 **2.2.1 Population PK/PD model and simulation**

66 A previously published population PK/PD analysis of rivaroxaban was used in our
67 study ²⁴. The study cohorts were obtained from a subset of patients in the largest
68 multinational phase III ROCKET AF trial (Rivaroxaban once daily Oral direct factor
69 Xa inhibition Compared with vitamin K antagonism for prevention of stroke and
70 Embolism Trial in Atrial Fibrillation) ²⁵. A total of 161 patients with NVAf, with
71 time-matched PK and PD samples were included in this population PK/PD analysis.
72 These included 136 patients with normal or mildly impaired renal function ($\text{CrCl} \geq 50$
73 mL/min) receiving 20 mg daily, and 25 patients with moderate renal impairment
74 (CrCl 30–49 mL/min) receiving 15 mg daily. Detailed demographic and dosing
75 regimen information is listed in [Supplementary Table 1](#). Blood samples were used to
76 determine rivaroxaban concentration, Factor Xa (FXa) activity, and prothrombin time
77 (PT).

78 In this analysis, population PK was depicted by a one-compartment model with
79 first-order absorption and elimination. The PK model was parameterised by the
80 absorption rate constant (k_a), apparent clearance (CL/F), and apparent volume of
81 distribution (V/F). The time-concentration relationship is described in Eq. 1.

$$C_p = \frac{k_a \cdot F \cdot \text{DOSE}}{V \cdot (k_a - \frac{CL}{V})} \cdot \left[\left(\frac{1 - e^{-\frac{CL}{V} \cdot n \cdot \tau}}{1 - e^{-\frac{CL}{V} \cdot \tau}} \cdot e^{-\frac{CL}{V} \cdot t} \right) - \left(\frac{1 - e^{-k_a \cdot n \cdot \tau}}{1 - e^{-k_a \cdot \tau}} \cdot e^{-k_a \cdot t} \right) \right] \quad (\text{Eq.1})$$

This equation comprised bioavailability (F), dose (DOSE; mg), apparent volume of distribution (V; L), number of doses administered (n), dosing interval (τ ; h), time after the last dose (t; h), and concentration at time t (C_p ; mg/L). Age and serum creatinine (SCr; mg/dL) affected CL/F (Eq 2.), while age and lean body mass (LBM) influenced V/F (Eq 3.).

$$CL/F \text{ (L/h)} = 6.1 \times (1 - 0.011 \times [\text{age} - 65] - 0.194 \times [\text{SCr} - 1.09]) \quad (\text{Eq. 2})$$

$$V/F \text{ (L)} = 79.7 \times (1 - 0.00133 \times [\text{age} - 65] + 0.0118 \times (\text{LBM} - 57.5)) \quad (\text{Eq. 3})$$

PD markers, including FXa activity and PT, were modelled to correlate with rivaroxaban concentration. FXa activity was negatively correlated with the concentration of rivaroxaban, with a direct inhibitory maximum-effect ($E_{\max}$) relationship, as described by Eq 4.

$$FXa = E_0 \times \left(1 - \frac{E_{\max} \times C_p}{EC_{50} + C_p} \right) \quad (\text{Eq.4})$$

where, E_0 represents baseline FXa activity, $E_{\max}$ represents the relative maximum level of inhibition, and EC_{50} represents the concentration of rivaroxaban resulting in 50% of maximum inhibition.

PT was positively correlated with rivaroxaban concentration in a near-linear relationship, as described by Eq 5.

$$PT = PT_0 + \text{slope} \cdot C_p^{1 - \text{exponent} \cdot C_p} \quad (\text{Eq.5})$$

PT₀ represents baseline PT, slope represents the per unit difference in CrCl (mL/min) to the median CrCl (76 mL/min), and the exponent represents the parameter describing the decline linearly with increasing C_p. CrCl was found to affect both PT₀ and the exponent, which is expressed by Eq.6 and Eq.7.

$$PT_0 = 11.4 \cdot (1 - 0.000192 \cdot [CrCl - 76]) \quad (\text{Eq.6})$$

$$\text{Exponent} = 0.0000551 \cdot (1 + 0.0174 \cdot [CrCl - 76]) \quad (\text{Eq.7})$$

All PK/PD parameter estimates employed in the Monte Carlo simulation are listed in Table 2.

Monte Carlo simulations were performed with NONMEM software (version 7.4; Icon Incorporation, PA, USA) using the \$SIMULATION block. Output profiles were processed using the R package (version 3.5.3, <https://www.r-project.org/>). A total of 5000 virtual patients were simulated to depict the PK/PD profiles under each non-adherence scenario. Virtual patients were assumed to have already received multiple doses of rivaroxaban and have reached steady state, and to obtain the expected level of anticoagulation without any unexpected drug-related adverse effects.

2.2.2 Remedial dosing regimens

Based on previous research and on clinical practise ²¹, six strategies, as well as recommendations included in the EHRA guide, assessed when the dose was delayed

120 or missed. Graphic remedial strategies are shown in [Figure 2](#), and details are below as

121 follows:

122 Strategy A: skip the delayed dose, administer the regular dose at the next scheduled
123 dosing time, and then resume the regular dosing regimen.

124 Strategy B: administer the regular dose immediately, followed by a regular dose at the
125 next scheduled dosing time, and then resume the regular dosing regimen.

126 Strategy C: administer a half dose immediately followed by a regular dose at the next
127 scheduled dosing time, and then resume the regular dosing regimen.

128 Strategy D: administer a regular dose immediately followed by a half dose at the next
129 scheduled dosing time, and then resume the regular dosing regimen.

130 Strategy E: administer one and a half regular doses immediately, skip the next
131 scheduled dose, and then resume the regular dosing regimen.

132 Strategy F: administer a double dose, skip a dose at the next scheduled dosing time,
133 and then resume the regular dosing regimen;

134 EHRA guide: administer the delayed dose if less than 12 h late; otherwise, skip the
135 delayed or missed dose and administer the next scheduled dose.

136 **2.2.3 Index for evaluating remedial regimens**

137 Currently, there is no widely accepted therapeutic range of rivaroxaban concentrations,
138 FXa activity, or PT. Therefore, the on-therapy range, defined as the ‘interval
139 delineated by the 5th percentile trough concentration and the 95th percentile peak

140 concentration' at the steady state of a given dose ^{26,27}, was used in this study.

141 Considering the differences in patient demographics, we estimated the on-therapy

142 range for each typical patient at steady state by Monte Carlo simulation. To assess the

143 effect of a delayed or missed dose, we defined the percentage of individuals outside

144 the on-therapy range as those whose concentration or PD marker levels were not

145 within the on-therapy range. The percentages of individuals outside the on-therapy

146 range under all non-adherence scenarios described above were estimated to evaluate

147 the effect of non-adherence over time.

148 Deviation time, defined as the duration when simulated rivaroxaban concentration,

149 FXa activity or PT are outside the on-therapy range, was chosen as the index to

150 evaluate the remedial regimen. It was calculated by adding each deviation time when

151 simulated data is higher than the upper limit and lower than the lower limit of

152 on-therapy range. The two aspects of deviation time may represent higher risk of

153 bleeding and thromboembolic events, respectively. It was assumed that patients taking

154 regular rivaroxaban doses had reached expected anticoagulant effects within the

155 on-therapy range. Therefore, when the rivaroxaban dose was delayed or missed,

156 optimal remedial dosing could help patients to restore the rivaroxaban concentration,

157 FXa, or PT to the on-therapy range as soon as possible to minimise the deviation time.

158 Two remedial dosing regimens with deviation times of less than 1 h were assumed to

159 be equivalent. If there were discrepancies among recommendations for rivaroxaban

160 concentration, FXa activity, or PT, those based on FXa activity were prioritised. This

161 was because quantification of FXa activity is considered as a more specific biomarker
162 for NOACs, which is recommended by the International Society on Thrombosis and
163 Haemostasis American College of Chest Physicians guidelines ^{28,29}.

164 **2.2.4 Sensitivity analysis**

165 A sensitivity analysis was applied to identify parameters that had a substantial
166 influence on model output, and to determine the extent that these important
167 parameters contributed to the overall variability in model output ³⁰. Therefore, dosing
168 intervals and demographic characteristics (age and body weight) were included in the
169 sensitivity analysis to investigate their influence on the remedial dosing regimens.

170 Irregular dosing intervals of 23–25 h (18:00, 17:00, and 18:00) and 25–23 h (18:00,
171 19:00, and 18:00) were assessed considering situations where patients took
172 rivaroxaban at different times every day. Moreover, considering the demographics of
173 the modelling population, patients with different ages and body weights (expressed as
174 LBM in population analysis) were also investigated ([Supplementary Table 2](#)).
175 Furthermore, the criterion used to judge the equality of the two strategies was also
176 examined from 0.5 to 2 h, to investigate whether it had an influence on the remedial
177 dosing recommendations.

178 **3 Results**

179 **3.1 Effect of delayed or missed doses of rivaroxaban on PK/PD**

180 The results from the Monte Carlo simulation showed that the effect of a delayed dose
181 was related to the delay time. With an increasing delay time, the risk of a patient
182 being outside the on-therapy range was also increased considering both the PK and
183 PD (Figure 3). For example, among patients with CrCl of 80 mL/min who took
184 rivaroxaban 20 mg q24h, 12.6% and 47.9% patients were outside the on-therapy
185 range based on rivaroxaban concentration when the dose was delayed for 6 h and 24 h,
186 respectively.

187 The effect of delayed dose was not significantly affected by age or renal function.
188 (Figure 3). For example, among elderly patients with normal renal function and
189 impaired renal function, the percentage of those who were outside the on-therapy
190 concentration range was 22.6% and 20.4% when the dose was delayed for 12 h,
191 respectively, representing a difference less than 15%. Moreover, the difference in the
192 percentages of patients who were outside of the FXa activity (8.6 vs. 8.26%) or PT
193 on-therapy (10.2 vs. 10.1%) range were also less than 15%.

194 In addition, the impact of the delayed dose on the PK/PD was very similar when the
195 delay time was less than 3 h. However, the difference increased as the delay time
196 increased (Figure 3). Considering rivaroxaban concentration, this percentage
197 increased approximately linearly with time. The percentage changes considering FXa
198 activity and PT were close, with a smaller slope and increased with the delay time.
199 For example, for adult patients receiving a 20 mg q24h dose delayed for 2 h, the
200 percentages of those outside the on-therapy range were 6.9, 6.5, and 6.4% for

201 rivaroxaban concentration, FXa activity, and PT, respectively. These percentages
202 were 23.4, 7.6, and 9.3%, respectively, when dosing was delayed for 12 h, with a
203 greater difference between rivaroxaban concentration and PD markers compared with
204 that at 2 h.

205 **3.2 Remedial dosing regimens**

206 The remedial dosing recommendations following a delayed rivaroxaban dose are
207 summarised in [Table 3](#). [Figure 4a–c](#) shows the concentration, FXa activity, and PT
208 profiles for fully adherent elderly patients with impaired renal function (aged 75 years,
209 CrCl 40 mL/min, receiving 15 mg q24h). In general, remedial dosing
210 recommendations are related to delayed time. A regular dose of rivaroxaban could be
211 taken immediately when the delay doesn't exceed 6 h. When the delay exceeds 6 h
212 but is less than 20 h, it is advisable to remedy a half dose either by taking a half dose
213 immediately followed by a regular dose at the next scheduled time (6–14 h), or by
214 taking a regular dose immediately followed by a half dose at the next scheduled
215 dosing time (14–20 h). When the delay exceeds 20 h, it is recommended to skip the
216 delayed dose and take a regular dose at the next scheduled dosing time. When a dose
217 is missed, it is advisable to take a regular dose at the scheduled dosing time.

218 Recommendations based on rivaroxaban concentration and FXa or PT levels were the
219 same among almost all scenarios, except for scenarios where the delay time was 3–6 h.
220 Rivaroxaban concentration, FXa activity, and PT profiles following a delay of 6 h

221 under optimal remedial regimens for elderly patients with impaired renal function
 222 (aged 75 years, CrCl 40 mL/min, taking 15 mg q24h) are shown in [Figure 4d–f](#).
 223 Under this scenario, recommendations based on FXa activity supported taking a
 224 regular dose immediately, while recommendations based on concentration and PT
 225 preferred taking a half dose. Based on pre-established criteria where FXa activity was
 226 preferred, recommendations based on FXa activity were selected.
 227 Additionally, age and renal function did not affect remedial dosing regimens. For
 228 example, for adult patients with normal renal function, a half dose (10 mg) is
 229 recommended when the dose is delayed by 6–20 h, based on rivaroxaban
 230 concentration, FXa activity, and PT. For elderly patients with impaired renal function
 231 taking a lower daily dose, a half dose (7.5 mg) is also recommended when the delay
 232 was 6–20 h.
 233 Because recommendations from the EHRA did not consider splitting rivaroxaban
 234 tablets, this represented a missed opportunity to provide a more personalised remedial
 235 strategy. Based on the present results, our recommendation is consistent with that of
 236 the EHRA only when the delay was less than 3 h, or it was less than 4 h before the
 237 next dose. Recommendations from the EHRA guide are not optimised for most
 238 scenarios. A comparison of the deviation time between the EHRA guide and our
 239 proposed remedial strategy is shown in [Figure 5](#). Deviation times under different
 240 strategies are listed in [Supplementary Table 3–6](#), which can provide supportive
 241 information to balance the risk of thromboembolism and bleeding.

242 3.3 Sensitivity analysis

243 Age, body weight, dosing intervals, and criterion for assessing the equality of the two
 244 strategies were included in the sensitivity analysis when the rivaroxaban dose was
 245 delayed for 3, 6, 12, and 24 h. Deviation time may vary slightly by age, body weight,
 246 and dosing intervals. However, these factors did not significantly impact remedial
 247 dosing regimens ([Supplementary Figure 1](#)). Broadening the criterion for assessing the
 248 equality of the two strategies resulted in more options for remedial strategies at some
 249 time points, whereas narrowing the criterion resulted in fewer options ([Supplementary](#)
 250 [Tables 7–10](#)). As shown in [Table 3](#), for adult patients with normal renal function,
 251 recommendations included 10 mg with strategy C or 20 mg with strategy B when
 252 there was a delay of 4 h considering the PT. However, the recommended strategy only
 253 included 10 mg with strategy C when the criteria were narrowed. When the criteria
 254 were broadened, 10 mg with strategy D was included in the recommended strategies.

255 4 Discussion

256 This was the first study to characterise the effects of delayed rivaroxaban dose on the
 257 PK/PD profiles and to investigate appropriate remedial dosing regimens for patients
 258 with NVAf under different scenarios. A few studies have estimated the rate of
 259 non-adherence of NOACs and explored the associated risk factors ^{12,13,15}. However,
 260 non-adherence is common, and very few studies have proposed solutions when doses
 261 are delayed or missed. Considering the high risk for thromboembolism resulting from

262 non-adherence and the serious consequences resulting from inappropriate remedial
263 and missing/delayed doses, our study is the first to provide insight into remedial
264 regimens for patients with NVAf following delayed or missed rivaroxaban doses.
265 Our study explored optimal remedial regimens based on Monte Carlo simulation from
266 the perspective of both PK and PD, and considering both population level and
267 individual variation. Handling delayed doses from the population PK perspective has
268 been previously discussed for various diseases, such as epilepsy³¹⁻³⁴, schizophrenia
269 ^{35,36} and renal transplantation ³⁷. However, few studies have explored this with
270 consideration of PD, or PK/PD ²¹. The PD effect should also be considered for
271 medicine acting via an indirect mechanism ³⁸, such as rivaroxaban, which acts as an
272 indirect anticoagulant by inhibiting FXa activity.
273 Multiple PK and PD markers were used in our study, including rivaroxaban
274 concentration, FXa activity, and PT. Given that no clearly defined therapeutic ranges
275 have been established for rivaroxaban ²⁶, an on-therapy range was adopted to describe
276 appropriate maintained levels of concentration, FXa activity, and PT. The concept of
277 an on-therapy range has been used for antiepileptic drugs, and was thought to be
278 appropriate for epilepsy management ^{32,33}. Regarding rivaroxaban, the calculated PK
279 on-therapy ranges based on simulated data are close to those estimated in clinical
280 trials ³⁹. We hypothesised that patients taking the prescribed dose could obtain
281 expected anticoagulation outcomes within the on-therapy range. It is reasonable to
282 assume that a remedial strategy restoring drug concentrations to a previous range can

283 minimise negative outcomes associated with non-adherence, such as lower exposure,
284 in addition to potential thromboembolic events.

285 Through population analysis and Monte Carlo simulation, our study provides
286 remedial dosing recommendations that are more time-specific than those included in
287 the EHRA guide. Recommendations from the EHRA are general for all NOACs,
288 including rivaroxaban, apixaban, edoxaban, and dabigatran ¹⁹. Our research optimises
289 these recommendations from both PK and PD perspectives, suggesting that the cut-off
290 point for remedying a full dose is not 12 h, as noted in the EHRA guide. Based on the
291 concentration and PT, the cut-off point is approximately 3 h, while based on FXa
292 activity, the cut-off is approximately 6 h. When the dose is delayed for less than the
293 cut-off point, taking the delayed dose of rivaroxaban as soon as possible is
294 recommended. However, when the delay exceeds the cut-off point, a half dose is
295 advisable, to minimise the deviation time. When the dose is close to the next
296 scheduled dose or is completely skipped, it is advisable to skip the missed dose and to
297 continue with the regular dosing regimen at the next scheduled time.

298 It is also notable that doubling the dose of rivaroxaban after a missed dose (strategy F)
299 is not recommended based on the drug package insert, the EHRA guide, and our
300 research. In fact, even remedying a half dose (strategy E) is unnecessary. This is
301 inconsistent with the findings of previous similar studies exploring remedial dosing
302 strategies in simulations based on antiepileptic drugs ³²⁻³⁴ or immunosuppressants ³⁷,
303 which are taken every 12 or 24 h. Remedying no extra dose when missing a dose may

304 result in a deviation time that is below the lower limit of the on-therapy range, while
 305 remedying a half dose increases the deviation time above the upper limit of the
 306 on-therapy range. Furthermore, a double dose substantially increases the drug
 307 concentration to levels beyond the upper limit of the on-therapy range. This also leads
 308 to a much longer deviation time outside the on-therapy range.

309 The risk of bleeding or thromboembolism varies among patients with atrial fibrillation.
 310 The CHA2DS2-VASc (congestive heart failure, hypertension, age ≥ 75 years,
 311 diabetes mellitus, stroke or transient ischaemic attack [TIA], vascular disease, age
 312 65–74 years, sex category) score is commonly used for the assessment of stroke risk
 313 ⁴⁰. The risk of stroke may differ for patients of the same age and with the same renal
 314 function, considering other factors included in the CHA2DS2-VASc scoring system.

315 Adherence to anticoagulant therapy, such as with rivaroxaban, is particularly
 316 important for patients with a high CHA2DS2-VASc score, given their high risk for
 317 stroke ³⁸. For example, in patients with a history of bleeding, it is important to avoid
 318 an inappropriate remedial strategy. Therefore, deviation times that exceed the upper
 319 limit of the on-therapy range and that were below the lower limit of the on-therapy
 320 range, representing the risk of bleeding and thromboembolism, respectively, are also
 321 listed in [Supplementary Tables 3–6](#). Therefore, clinicians can select the optimal
 322 remedial dose for individual patients based on deviation time and patient
 323 characteristics.

324 There are several limitations to this study. First, the simulated dosing regimen
325 complied with that of the modelling population, who took 20 or 15 mg daily
326 rivaroxaban based on renal function. Therefore, our recommendations may not apply
327 to patients receiving other doses of rivaroxaban. Second, our recommendations were
328 based on a 90% predicted interval of simulation data. Therefore, attention should be
329 paid to special populations, such extremely obese patients or older patients, who were
330 not included in our analysis.

331 In conclusion, this study assessed the effect of non-adherence to rivaroxaban and
332 explored appropriate remedial dosing regimens for patients with NVAf considering
333 the drug concentration, FXa, and PT. According to our model-informed analysis, the
334 optimal remedial strategy is only dependent on the duration of the delay. We
335 recommend that a rivaroxaban dose is taken following a delay of no more than 6 h,
336 while a half dose may be recommended after 6 h up to a maximum of 4 h before the
337 next dose. No dose is advisable to remedy a missed dose. Clinicians should also
338 balance the risk of bleeding and stroke and select appropriate remedial strategies
339 based on the clinical situation of each patient.

340

341 **Acknowledges**

342 We thank Dr. I.G. Girgis from Janssen Pharmaceuticals Research & Development,
343 Raritan, USA for providing details and active discussions on the coding. We thank
344 Hai-ni Wen MPharm., and Yun-peng Guo MPharm. from Shanghai Chest Hospital for

345 their critical comments. We would also thank Editage (www.editage.cn) for English
346 language editing.

347

348 **Competing interest**

349 The authors have no conflict of interest to disclose.

350

351 **Funding**

352 None.

353

354 **Author contributions**

355 Xiao-qin Liu, Yi-wei Yin, and Zheng Jiao designed the article and planned the work
356 for the manuscript. Xiao-qin Liu, Chen-yu Wang, Zi-ran Li performed the data
357 analysis. Xiao-qin Liu, Yi-wei Yin, Xiao Zhu, and Zheng Jiao drafted and revised the
358 manuscript. All authors approved the final version of this manuscript.

359 **Reference**

- 360 1. Misselwitz F, Berkowitz SD, Perzborn E. The discovery and development of
361 rivaroxaban. *Ann N Y Acad Sci.* 2011;1222:64-75.
- 362 2. FDA. XARELTO® [insert package]. 2020;
363 https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202439s031,02240
364 [6s0351bl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202439s031,022406s0351bl.pdf).
- 365 3. Loo SY, Dell'Aniello S, Huiart L, Renoux C. Trends in the prescription of novel
366 oral anticoagulants in UK primary care. *Br J Clin Pharmacol.*
367 2017;83(9):2096-2106.
- 368 4. Zhu J, Alexander GC, Nazarian S, Segal JB, Wu AW. Trends and Variation in
369 Oral Anticoagulant Choice in Patients with Atrial Fibrillation, 2010-2017.
370 *Pharmacotherapy.* 2018;38(9):907-920.
- 371 5. Maggioni AP, Dondi L, Andreotti F, et al. Four-year trends in oral anticoagulant
372 use and declining rates of ischemic stroke among 194,030 atrial fibrillation
373 patients drawn from a sample of 12 million people. *Am Heart J.*
374 2020;220:12-19.
- 375 6. Mueck W, Stampfuss J, Kubitz D, Becka M. Clinical pharmacokinetic and
376 pharmacodynamic profile of rivaroxaban. *Clinical pharmacokinetics.*
377 2014;53(1):1-16.

- 378 7. Kvasnicka T, Malikova I, Zenahlikova Z, et al. Rivaroxaban - Metabolism,
379 Pharmacologic Properties and Drug Interactions. Curr Drug Metab.
380 2017;18(7):636-642.
- 381 8. Fox KA, Piccini JP, Wojdyla D, et al. Prevention of stroke and systemic
382 embolism with rivaroxaban compared with warfarin in patients with
383 non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J.
384 2011;32(19):2387-2394.
- 385 9. Pham PN, Brown JD. Real-world adherence for direct oral anticoagulants in a
386 newly diagnosed atrial fibrillation cohort: does the dosing interval matter? BMC
387 Cardiovasc Disord. 2019;19(1):64.
- 388 10. Kim D, Yang PS, Jang E, et al. 10-year nationwide trends of the incidence,
389 prevalence, and adverse outcomes of non-valvular atrial fibrillation nationwide
390 health insurance data covering the entire Korean population. Am Heart J.
391 2018;202:20-26.
- 392 11. Weber C, Hung J, Hickling S, et al. Drivers of hospitalisation trends for
393 non-valvular atrial fibrillation in Western Australia, 2000-2013. Int J Cardiol.
394 2019;276:273-277.
- 395 12. Rodriguez-Bernal CL, Peiró S, Hurtado I, García-Sempere A, Sanfélix-Gimeno
396 G. Primary Nonadherence to Oral Anticoagulants in Patients with Atrial
397 Fibrillation: Real-World Data from a Population-Based Cohort. J Manag Care
398 Spec Pharm. 2018;24(5):440-448.

- 399 13. Reading SR, Black MH, Singer DE, et al. Risk factors for medication
400 non-adherence among atrial fibrillation patients. BMC Cardiovasc Disord.
401 2019;19(1):38-38.
- 402 14. Moll S, Berkowitz JN, Miars CW. Elite athletes and anticoagulant therapy: an
403 intermittent dosing strategy. Hematology Am Soc Hematol Educ Program.
404 2018;2018(1):412-417.
- 405 15. Deshpande CG, Kogut S, Laforge R, Willey C. Impact of medication adherence
406 on risk of ischemic stroke, major bleeding and deep vein thrombosis in atrial
407 fibrillation patients using novel oral anticoagulants. Curr Med Res Opin.
408 2018;34(7):1285-1292.
- 409 16. Reilly PA, Lehr T, Haertter S, et al. The effect of dabigatran plasma
410 concentrations and patient characteristics on the frequency of ischemic stroke
411 and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized
412 Evaluation of Long-Term Anticoagulation Therapy). J Am Coll Cardiol.
413 2014;63(4):321-328.
- 414 17. Electronic medicines compendium. Xarelto 20/15mg film-coated tablets
415 [Package leaflet: Information for the user]. 2020;
416 <https://www.medicines.org.uk/emc/files/pil.2793.pdf>.
- 417 18. New Zealand Medicines and Medical Devices Safety Authority.
418 XARELTO®[Consumer Medicine Information]. 2020;
419 <https://www.medsafe.govt.nz/Consumers/CMI/x/Xarelto.pdf>.

- 420 19. Steffel J, Verhamme P, Potpara TS, et al. The 2018 European Heart Rhythm
421 Association Practical Guide on the use of non-vitamin K antagonist oral
422 anticoagulants in patients with atrial fibrillation. *Eur Heart J*.
423 2018;39(16):1330-1393.
- 424 20. Vrijens B, Heidbuchel H. Non-vitamin K antagonist oral anticoagulants:
425 considerations on once- vs. twice-daily regimens and their potential impact on
426 medication adherence. *Europace*. 2015;17(4):514-523.
- 427 21. Gu JQ, Guo YP, Jiao Z, Ding JJ, Li GF. How to Handle Delayed or Missed
428 Doses: A Population Pharmacokinetic Perspective. *Eur J Drug Metab*
429 *Pharmacokinet*. 2020;45(2):163-172.
- 430 22. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum
431 creatinine. *Nephron*. 1976;16(1):31-41.
- 432 23. Schmidt M, Ulrichsen SP, Pedersen L, et al. 30-year nationwide trends in
433 incidence of atrial fibrillation in Denmark and associated 5-year risk of heart
434 failure, stroke, and death. *Int J Cardiol*. 2016;225:30-36.
- 435 24. Girgis IG, Patel MR, Peters GR, et al. Population pharmacokinetics and
436 pharmacodynamics of rivaroxaban in patients with non-valvular atrial
437 fibrillation: results from ROCKET AF. *Journal of clinical pharmacology*.
438 2014;54(8):917-927.
- 439 25. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in
440 nonvalvular atrial fibrillation. *N Engl J Med*. 2011;365(10):883-891.

- 441 26. Cuker A, Siegal D. Monitoring and reversal of direct oral anticoagulants.
442 Hematology Am Soc Hematol Educ Program. 2015;2015:117-124.
- 443 27. Samuelson BT, Cuker A. Measurement and reversal of the direct oral
444 anticoagulants. Blood Rev. 2017;31(1):77-84.
- 445 28. Ageno W, Gallus AS, Wittkowsky A, et al. Oral anticoagulant therapy:
446 Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American
447 College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest.
448 2012;141(2 Suppl):e44S-e88S.
- 449 29. Baglin T, Hillarp A, Tripodi A, et al. Measuring Oral Direct Inhibitors (ODIs)
450 of thrombin and factor Xa: A recommendation from the Subcommittee on
451 Control of Anticoagulation of the Scientific and Standardisation Committee of
452 the International Society on Thrombosis and Haemostasis. J Thromb Haemost.
453 2013;11(4):756-760.
- 454 30. Zhang XY, Trame MN, Lesko LJ, Schmidt S. Sobol Sensitivity Analysis: A
455 Tool to Guide the Development and Evaluation of Systems Pharmacology
456 Models. CPT Pharmacometrics Syst Pharmacol. 2015;4(2):69-79.
- 457 31. Wang CY, jiao Z, Ding JJ, Yu EQ, Zhu GX. Remedial dosing recommendations
458 for delayed or missed doses of valproic acid in patients with epilepsy based on
459 Monte Carlo simulations. Epilepsy Behav. 2020;111:107265 [Online ahead of
460 print].

- 461 32. Yu EQ, Jiao Z, Wang CY, Ding JJ, Zhang XH. Remedial dosing
462 recommendations for delayed or missed doses of lamotrigine in pediatric
463 patients with epilepsy using Monte Carlo simulations. *Epilepsy Behav.*
464 2019;96:132-140.
- 465 33. Ding JJ, Zhang YJ, Jiao Z, Wang Y. The effect of poor compliance on the
466 pharmacokinetics of carbamazepine and its epoxide metabolite using Monte
467 Carlo simulation. *Acta Pharmacol Sin.* 2012;33(11):1431-1440.
- 468 34. Dutta S, Reed RC. Effect of delayed and/or missed enteric-coated divalproex
469 doses on valproic acid concentrations: simulation and dose replacement
470 recommendations for the clinician. *J Clin Pharm Ther.* 2006;31(4):321-329.
- 471 35. Magnusson MO, Samtani MN, Plan EL, et al. Dosing and Switching Strategies
472 for Paliperidone Palmitate 3-Month Formulation in Patients with Schizophrenia
473 Based on Population Pharmacokinetic Modeling and Simulation, and Clinical
474 Trial Data. *CNS Drugs.* 2017;31(4):273-288.
- 475 36. Hard ML, Wehr AY, Sadler BM, Mills RJ, von Moltke L. Population
476 Pharmacokinetic Analysis and Model-Based Simulations of Aripiprazole for a
477 1-Day Initiation Regimen for the Long-Acting Antipsychotic Aripiprazole
478 Lauroxil. *Eur J Drug Metab Pharmacokinet.* 2018;43(4):461-469.
- 479 37. Saint-Marcoux F, Woillard JB, Monchaud C, et al. How to handle missed or
480 delayed doses of tacrolimus in renal transplant recipients? A pharmacokinetic
481 investigation. *Pharmacol Res.* 2015;100:281-287.

- 482 38. Whitlon DS, Sadowski JA, Suttie JW. Mechanism of coumarin action:
483 significance of vitamin K epoxide reductase inhibition. *Biochemistry*.
484 1978;17(8):1371-1377.
- 485 39. Siguret V, Abdoul J, Delavenne X, et al. Rivaroxaban pharmacodynamics in
486 healthy volunteers evaluated with thrombin generation and the active protein C
487 system: Modeling and assessing interindividual variability. *Journal of*
488 *Thrombosis and Haemostasis*. 2019;17(10):1670-1682.
- 489 40. January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS Focused Update
490 of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With
491 Atrial Fibrillation: A Report of the American College of Cardiology/American
492 Heart Association Task Force on Clinical Practice Guidelines and the Heart
493 Rhythm Society in Collaboration With the Society of Thoracic Surgeons.
494 *Circulation*. 2019;140(2):e125-e151.
- 495

Figure legends

Fig. 1 Simulation scenarios for delayed or missed rivaroxaban doses for patients with non-valvular atrial fibrillation (NVAf) receiving 15 or 20 mg dose every 24 h.

Fig. 2 Graphical representation of six remedial dosing regimens following a delayed or missed dose. Represents an integrated rivaroxaban dose, and represents a half rivaroxaban dose. Patients were assumed to take rivaroxaban at 18:00 daily and to have reached a steady state following a delayed or missed dose.

^a n represents the delayed time, whose range is from 1 to 24 h.

Fig. 3 Percentage of patients with NVAf falling outside the on-therapy ranges *versus* time after the delayed or missed doses in terms of rivaroxaban concentration, FXa activity and PT. (a) Adult patients, 55 years old, CrCl 80 mL/min receiving 20 mg every 24 h (q24h). (b) Adult patients, 55 years old, CrCl 40 mL/min receiving 15 mg q24h. (c) Elderly patients, 75 years old, CrCl 80 mL/min receiving 20 mg q24h. (d) Elderly patients, 75 years old, CrCl 40 mL/min receiving 15 mg q24h. Simulated patients were assumed to take rivaroxaban doses regularly and to have reached steady state.

Fig. 4 Pharmacokinetic (PK) and pharmacodynamic (PD) profiles under full adherence and optimal remedial regimens in terms of rivaroxaban concentration, FXa

activity and PT for elderly patient with CrCl 40 mL/min receiving rivaroxaban 15 mg every 24 h when the dose was delayed for 6 h. (a) Full adherence based on concentration, (b) FXa activity, and (c) PT. (d) optimal remedial regimens in terms of concentration, (e) FXa activity, and (f) PT when the dose was delayed for 6 h. Dark pink shadows represent the distribution of the range between the 5th percentile of the simulated trough concentration (FXa activity or PT) and 95th percentile of the simulated peak concentration (FXa activity or PT). Light pink shadows represent the distribution of the remaining simulated concentration (FXa activity or PT). Red solid lines represent the median of the simulated concentration (FXa activity or PT). The red dotted lines represent the 0.5th percentile and 99.5th percentile of the simulated concentration (FXa activity or PT). Black dotted lines represent the on-therapy range calculated by the simulated concentration (FXa activity or PT). Black horizontal bold solid lines represent the deviation time.

Fig. 5 Total deviation time from recommendations by the European Heart Rhythm Association (EHRA) guide and proposed remedial regimens. (a) Adult patients, 55 years old, CrCl 80 mL/min taking 20 mg every 24 h (q24h). (b) Adult patients, 55 years old, CrCl 40 mL/min taking 15 mg q24h. (c) Elderly patients, 75 years old, CrCl 80 mL/min taking 20 mg q24h. (d) Elderly patients, 75 years old, CrCl 40 mL/min taking 15 mg q24h. Simulated patients were assumed to take rivaroxaban doses regularly and to have reached steady state.

Table

Table 1 Demographic characteristics of simulated patients and corresponding dosing regimens.

ID	Age	BW	LBM ^a	SCr	CrCl ^b	Dose regimen
	(years)	(kg)	(kg)	(mg/dL)	(mL/min)	
1	55	70	55	1.03	80	20 mg q24h
2	55	70	55	2.07	40	15 mg q24h
3	75	70	55	0.79	80	20 mg q24h
4	75	70	55	1.58	40	15 mg q24h

Abbreviations: LBM, lean body mass; BW, body weight; SCr, serum creatinine; CrCl, creatinine clearance.

^a Calculated lean body mass (LBM) in [kg]. for males: $LBM (kg) = 1.10 \cdot (weight (kg)) - 128 \cdot$

$\left(\frac{weight (kg)}{height (cm)}\right)^2$; for females: $LBM (kg) = 1.07 \cdot (weight (kg)) - 148 \cdot \left(\frac{weight (kg)}{height (cm)}\right)^2$.

^b Calculated creatinine clearance by Cockcroft-Gault formula in [mL/min]. for males: $CrCl (mL/min) =$

$\frac{(140 - age(years)) \cdot (weight (kg))}{72 \cdot SCr (mg/dL)}$; for females: $CrCl (mL/min) = \frac{(140 - age(years)) \cdot (weight (kg))^{0.85}}{72 \cdot SCr (mg/dL)}$.

Table 2 Population pharmacokinetic/pharmacodynamic (PK/PD) parameter estimates

used in the Monte Carlo simulation²⁴

PK and PD parameter (units) and formula			BSV	WSV
			(%)	(%)
PK	$C_p = \frac{k_a \times F \times \text{DOSE}}{V \times (k_a - \frac{CL}{V})} \times \left[\left(\frac{1 - e^{-\frac{CL}{V} \times n \times \tau}}{1 - e^{-\frac{CL}{V} \times \tau}} \times e^{-\frac{CL}{V} \times t} \right) - \left(\frac{1 - e^{-k_a \times n \times \tau}}{1 - e^{-k_a \times \tau}} \times e^{k_a \times t} \right) \right]$			
	k_a (h)	= 1.16	/	47.9
	CL/F (L/h)	= $6.10 \times (1 - 0.011 \times [\text{age} - 65] - 0.194 \times [\text{SCr} - 1.09])$	35.2	
	V/F (L)	= $79.7 \times (1 - 0.00133 \times [\text{age} - 65] + 0.0118 \times [\text{LBM} - 57.5])$	17.6	
FXa activity	$\text{FXa (\%)} = E_0 \times \left(1 - \frac{E_{\max} \times C_p}{EC_{50} + C_p} \right)$			
	E_0	= 104% ^a	16.61	10.05
	$E_{\max}$	= 107%	/	
	EC_{50} (μg/L)	= 760	5.97	
PT	$PT = PT_0 + \text{slope} \times C_p^{1 - \text{exponent} \times C_p}$			
	PT_0 (s)	= $11.40 \times (1 - 0.000192 \times [\text{CrCl} - 76])$	22.6	12.9
	slope	= 0.0426	/	
	exponent	= $0.0000551 \times (1 + 0.0174 \times [\text{CrCl} - 76])$	4.42	

Abbreviations: PK, pharmacokinetics; k_a , absorption rate constant; CL/F, apparent oral clearance; V/F, volume of distribution; FXa, factor Xa; PT, prothrombin time; BSV, between-subject variability; WSV, within-subject variability.

^a E₀ was reported to be affected by age moderately, but parameter estimate was not shown.

Notes: data is from Girgis IG, Patel MR, Peters GR, et al. J Clin Pharmacol, 2014, 54 (8): 917-27.

Table 3 Remedial dosing recommendations for patients with atrial fibrillation

Regimen	Delayed time (h)	Dose recommendations and strategies ^a based on		
		concentration	FXa	PT
20 mg q24h	0-2	20-20 [B/EHRA]	20-20 [B/EHRA]	20-20 [B/EHRA]
(55 years old, CrCl 80 mL/min)	2-3	20-20 [B/EHRA]/	20-20 [B/EHRA]	20-20 [B/EHRA]/
		10-20 [C]		10-20 [C]
	3-4	10-20 [C]	20-20 [B/EHRA]	10-20 [C]/ 20-20 [B/EHRA]
	4-6	10-20 [C]	20-20 [B/EHRA]	10-20 [C]
	6-7	10-20 [C]	10-20 [C]/20-20 [B]	10-20 [C]
	7-10	10-20 [C]	10-20 [C]	10-20 [C]
	10-12	10-20 [C]	10-20 [C]	10-20 [C]/ 20-10 [D]
	12-14	10-20 [C]/ 20-10 [D]	10-20 [C]	20-10 [D]
	14-16	10-20 [C]/ 20-10 [D]	10-20 [C]/20-10 [D]	20-10 [D]
	16-18	20-10 [D]	20-10 [D]	20-10 [D]
	18-20	20-10 [D]	0-20 [A/EHRA]	20-10 [D]
	20-24	0-20 [A/EHRA]	0-20 [A/EHRA]	0-20 [A/EHRA]

Table 3 (continued)

Regimen	Delayed time (h)	Dose recommendations and strategies ^a based on		
		concentration	FXa	PT
20 mg q24h	0-2	20-20 [B/EHRA]	20-20 [B/EHRA]	20-20 [B/EHRA]
(75 years old, CrCl 80 mL/min)	2-3	20-20 [B/EHRA]/	20-20 [B/EHRA]	20-20 [B/EHRA]/
		10-20 [C]		10-20 [C]
	3-4	10-20 [C]	20-20 [B/EHRA]	10-20 [C]/ 20-20 [B/EHRA]
	4-6	10-20 [C]	20-20 [B/EHRA]	10-20 [C]
	6-10	10-20 [C]	10-20 [C]	10-20 [C]
	10-14	10-20 [C]	10-20 [C]	10-20 [C]/ 20-10 [D]
	14-16	20-10 [D]	10-20 [C]/20-10 [D]	20-10 [D]
	16-18	20-10 [D]	20-10 [D]	20-10 [D]
	18-20	20-10 [D]	20-10 [D]/10-20 [C]/ 0-20 [A/EHRA]	20-10 [D]
	20-22	0-20 [A/EHRA]	0-20 [A/EHRA]	0-20 [A/EHRA]/ 20-10 [D]
	22-24	0-20 [A/EHRA]	0-20 [A/EHRA]	0-20 [A/EHRA]

Table 3 (continued)

Regimen	Delayed time (h)	Dose recommendations and strategies ^a based on		
		concentration	FXa	PT
15 mg q24h	0-2	15-15 [B/EHRA]	15-15 [B/EHRA]	15-15 [B/EHRA]
(55 years old, CrCl 40 mL/min)	2-3	15-15 [B]/ 7.5-15 [C]	15-15 [B/EHRA]	15-15 [B]/7.5-15 [C]
	3-6	7.5-15 [C]	15-15 [B/EHRA]	7.5-15 [C]
	6-8	7.5-15 [C]	15-15 [B/EHRA]/ 7.5-15 [C]	7.5-15 [C]
	8-10	7.5-15 [C]	7.5-15 [C]	7.5-15 [C]
	10-12	7.5-15 [C]	7.5-15 [C]	7.5-15 [C]/15-7.5 [D]
	12-14	7.5-15 [C]/ 15-7.5 [D]	7.5-15 [C]	15-7.5 [D]
	14-16	7.5-15 [C]/ 15-7.5 [D]	7.5-15 [C]/ 15-7.5 [D]	15-7.5 [D]
	16-18	15-7.5 [D]	15-7.5 [D]	15-7.5 [D]
	18-20	15-7.5 [D]	15-7.5 [D]/0-15 [A]	15-7.5 [D]
	20-22	0-15 [A/EHRA]	0-15 [A/EHRA]	0-15 [A/EHRA]/ 15-7.5 [D]/7.5-15 [C]/ 22.5-0 [E]
	22-24	0-15 [A/EHRA]	0-15 [A/EHRA]	0-15 [A/EHRA]

Table 3 (continued)

Regimen	Delayed time (h)	Dose recommendations and strategies ^a based on		
		concentration	FXa	PT
15 mg q24h	0-3	15-15 [B/EHRA]	15-15 [B/EHRA]	15-15 [B/EHRA]
(75 years old, CrCl 40 mL/min)	3-4	15-15 [B/EHRA]/	15-15 [B/EHRA]	7.5-15 [C]/
		7.5-15 [C]		15-15 [B/EHRA]
	4-5	7.5-15 [C]/	15-15 [B/EHRA]	7.5-15 [C]
		15-15 [B]		
	5-6	7.5-15 [C]	15-15 [B/EHRA]	7.5-15 [C]
	7-8	7.5-15 [C]	15-15 [B/EHRA]/	7.5-15 [C]
			7.5-15 [C]	
	8-12	7.5-15 [C]	7.5-15 [C]	7.5-15 [C]
	12-14	7.5-15 [C]	7.5-15 [C]	7.5-15 [C]/15-7.5 [D]
	14-16	7.5-15 [C]/	7.5-15 [C]	15-7.5 [D]
		15-7.5 [D]		
	16-18	15-7.5 [D]	7.5-15 [C]/15-7.5 [D]	15-7.5 [D]
	18-20	15-7.5 [D]	15-7.5 [D]	15-7.5 [D]
	20-22	0-15 [A/EHRA]	0-15 [A/EHRA]/	0-15 [A/EHRA]/
			15-7.5 [D]	15-7.5 [D]/7.5-15 [C]

22-24 0-15 [A/EHRA] 0-15 [A/EHRA] 0-15 [A/EHRA]

Abbreviations: FXa, factor Xa; PT, prothrombin time; CrCl, creatinine clearance. EHRA, European Heart Rhythm Association

Notes: Simulated patients were assumed to take multiple rivaroxaban doses regularly and have reached steady state. Six strategies are A) skip the delayed dose, and administrate the regular dose at the next scheduled time, and then resume the regular dosing regimen; B) administrate a regular dose immediately, followed by a regular dose at the next scheduled time, and then resume the regular dosing regimen; C) administrate a half dose immediately followed by a regular dose at the next scheduled time, and then resume the regular dosing regimen; D) administrate a regular dose immediately followed by a half dose at the next scheduled time, and then resume the regular dosing regimen; E) administrate one and a half regular doses immediately and skip a dose at the next scheduled time, and then resume the regular dosing regimen; F) administrate double doses and skip a dose at the next scheduled time, and then resume the regular dosing regimen. EHRA guide: administrate the forgotten dose when it's less than 12 h later; otherwise skipped the dose and took and next scheduled dose.

^a “Dose recommendations” represent “dose taken immediately – dose taken at next schedule time”.

Strategies with difference in deviation time less than 1 h were considered to be equivalent.

Strategy	Day 1 18:00 (at steady state)	Day 2 18:00	Day 2/3 Delayed n h ^a	Day 3 18:00	Day 4 18:00	Day 5 18:00
A		Missed	Skip
B		Missed
C		Missed
D		Missed
E		Missed		Skip
F		Missed		Skip

Percentage of individuals outside on-therapy range(%)

Time after the delayed or missed dose (h)